Sugi Predict

Sugi Predict / Targets / PDHX

PDHX

Pyruvate dehydrogenase protein X component, mitochondrial · O00330 · PDHX on Sugi Atlas →

113 patent compounds predicted against PDHX, 87 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL22024879 SCHEMBL22024879 0.70 1/20
SCHEMBL4698765 SCHEMBL4698765 0.61 1/20
SCHEMBL22024880 SCHEMBL22024880 0.61 1/20
SCHEMBL4700718 SCHEMBL4700718 0.60 1/20
SCHEMBL4699844 SCHEMBL4699844 0.60 1/20
SCHEMBL2806838 SCHEMBL2806838 0.58 1/20
SCHEMBL14070193 SCHEMBL14070193 0.58 1/20
SCHEMBL4697700 SCHEMBL4697700 0.58 1/20
SCHEMBL21943483 SCHEMBL21943483 0.57 1/20
SCHEMBL22025542 SCHEMBL22025542 0.57 1/20
SCHEMBL14070255 SCHEMBL14070255 0.56 1/20
SCHEMBL4697113 SCHEMBL4697113 0.56 1/20
SCHEMBL4699434 SCHEMBL4699434 0.56 1/20
SCHEMBL14069588 SCHEMBL14069588 0.56 1/20
SCHEMBL20558521 SCHEMBL20558521 0.56 1/20
SCHEMBL4697958 SCHEMBL4697958 0.56 1/20
SCHEMBL4754278 SCHEMBL4754278 0.56 1/20
SCHEMBL14069862 SCHEMBL14069862 0.56 1/20
SCHEMBL14069733 SCHEMBL14069733 0.55 1/20
SCHEMBL29728053 SCHEMBL29728053 0.55 1/20

Clinical trials — most relevant to PDHX by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy PHASE4NOT_YET_RECRUITING
Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency: PHASE3ACTIVE_NOT_RECRUITING
Glutamate for Metabolic Intervention in Coronary Surgery PHASE3COMPLETED
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI) PHASE2RECRUITING
Thiamine as an Adjunctive Therapy in Cardiac Surgery PHASE2COMPLETED
Thiamine as Adjunctive Therapy for Diabetic Ketoacidosis PHASE2COMPLETED
Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder PHASE2WITHDRAWN
Use of Phenylbutyrate Therapy for Patients With Pyruvate Dehydrogenase Complex Deficiency. PHASE2COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy PHASE2ACTIVE_NOT_RECRUITING
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance PHASE2RECRUITING
Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13 Pyruvate EARLY_PHASE1ENROLLING_BY_INVITATION
Natural History Study of Pyruvate Dehydrogenase Deficiency nanUNKNOWN
Natural History and Advanced Genetic Study of Pyruvate Dehydrogenase Complex Deficiencies nanRECRUITING
Transcutaneous Electrical Diaphragmatic Stimulation in Critically Ill Elderly Patients nanUNKNOWN
Combined Effect of Exercise Intensity With Nutritional Supplementation on Skeletal Muscle Function nanCOMPLETED
UTSW HP [13-C] Pyruvate Injection in HCM nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Role of LDH as a Predictor of Treatment Outcomes in Hepatocellular Carcinoma nanUNKNOWN
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population nanUNKNOWN
Molecular Mechanisms of Exercise Benefits to Insulin Resistant People nanCOMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Baseline Physiology Studies in Carriers of Gene Variant X Conferring Major Risk of CVD-prone Metabolic Disorders nanCOMPLETED
Biologic Mechanisms for Pain Variation After Physical Activity in Osteoarthritis nanCOMPLETED
Alternative Substrates in the Critically Ill Subject nanCOMPLETED
Thiamine As An Adjuvant Therapy For Hyperlactatemia In Septic Shock Patients nanUNKNOWN
Lactate Profile and Fat Oxidation During Exercise nanCOMPLETED
Potential Synergistic Effect of Combined Blood Flow Restriction Training and Betaine Supplementation on Skeletal Muscle nanCOMPLETED
Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PDHX binder may also engage these)

ProteinNameSimilarity
Q8BKZ9 — 1.000 Q8BKZ9 →
Q9N0F1 — 0.997 Q9N0F1 →
P22439 — 0.996 P22439 →
Q9D2G2 — 0.996 Q9D2G2 →
Q0WQF7 — 0.992 Q0WQF7 →
P11179 — 0.990 P11179 →
DLAT Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial 0.989 landscape →
P19262 — 0.988 P19262 →
Q9FLQ4 — 0.987 Q9FLQ4 →
P86197 — 0.987 P86197 →
O94681 — 0.986 O94681 →
Q8BMF4 — 0.985 Q8BMF4 →
P11180 — 0.984 P11180 →
Q8H107 — 0.984 Q8H107 →
Q01205 — 0.984 Q01205 →
O59816 — 0.983 O59816 →
DLST Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial 0.982 landscape →
Q19749 — 0.982 Q19749 →
A8XFM8 — 0.981 A8XFM8 →
Q90512 — 0.981 Q90512 →
Q6CE48 — 0.980 Q6CE48 →
P75392 — 0.980 P75392 →
Q8K009 — 0.980 Q8K009 →
Q2QMG2 — 0.979 Q2QMG2 →
P08461 — 0.979 P08461 →
Q9S7G6 — 0.979 Q9S7G6 →
P11181 — 0.978 P11181 →
O44952 — 0.977 O44952 →
P0C585 — 0.977 P0C585 →
Q754Q9 — 0.977 Q754Q9 →